Galecto Past Earnings Performance
Past criteria checks 0/6
Galecto's earnings have been declining at an average annual rate of -8.8%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-8.8%
Earnings growth rate
78.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -118.6% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?
Jan 10Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely
May 17Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?
Feb 01Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer
Oct 19Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Oct 19Galecto GAAP EPS of -$0.67 beats by $0.02
Jul 29We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Jun 30Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?
Mar 10Galecto: Selling At Cash Value
Dec 19We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate
Nov 18Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Jul 07Galecto EPS misses by $0.07
May 04We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth
Mar 23Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?
Jan 29Galecto EPS misses by $41.65
Dec 11Revenue & Expenses BreakdownBeta
How Galecto makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -38 | 13 | 24 |
30 Sep 23 | 0 | -46 | 12 | 32 |
30 Jun 23 | 0 | -52 | 12 | 40 |
31 Mar 23 | 0 | -58 | 12 | 45 |
31 Dec 22 | 0 | -62 | 13 | 48 |
30 Sep 22 | 0 | -61 | 14 | 48 |
30 Jun 22 | 0 | -60 | 14 | 47 |
31 Mar 22 | 0 | -55 | 14 | 42 |
31 Dec 21 | 0 | -52 | 14 | 38 |
30 Sep 21 | 0 | -42 | 14 | 36 |
30 Jun 21 | 0 | -44 | 13 | 34 |
31 Mar 21 | 0 | -43 | 11 | 30 |
31 Dec 20 | 0 | -35 | 9 | 25 |
30 Sep 20 | 0 | -57 | 6 | 25 |
30 Jun 20 | 0 | -48 | 4 | 21 |
31 Mar 20 | 0 | -42 | 3 | 20 |
31 Dec 19 | 0 | -42 | 2 | 20 |
Quality Earnings: GLTO is currently unprofitable.
Growing Profit Margin: GLTO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLTO is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare GLTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: GLTO has a negative Return on Equity (-118.61%), as it is currently unprofitable.